Roots Analysis has done a detailed study on Ophthalmic Drugs Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms (Ophthalmic Drops, Emulsions, Gels, Injections, Lotions, Ointments, Suspensions, and Tablets / Capsules), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 375+ page report, which features 180+ figures and 195+ tables, please visit this link
Key Market Insights
- Over 240 companies across the globe claim to have the required capabilities to offer variety of services on a contract basis, working at different scales of operation, for a wide range of ophthalmic APIs and drug FDFs
- The market is fragmented, featuring the presence of both established players and small firms based in different geographies that claim to be capable of manufacturing ophthalmic products
- Presently, majority of the CMOs are offering services for ophthalmic drug FDFs packaged in a variety of formats; popular types of containers include glass / plastic bottles, ointment tubes and ampoules / vials
- In order to acquire competencies across the supply chain and cater to evolving needs of sponsors, companies have established presence across different regions, having been certified by various regulatory authorities
- Several players involved in this domain are steadily expanding their capabilities in order to enhance their respective service portfolios and maintain a competitive edge
- In the past few years, over 10,700 trials, enrolling approximately 4.6 million patients, suffering from a wide range of chronic eye conditions, have been registered across the globe by different sponsors
- Most of the installed, global ophthalmic drug manufacturing capacity belongs to larger and more established CMOs, accounting for over 80% of available capacity across various geographies
- The demand for manufacturing services for ophthalmic drug products is expected to increase in the coming years; we believe stakeholders may have to expand their respective capacities to ensure consistent supply
- We expect ophthalmic drug developers to continue to outsource their development and manufacturing operations in the short to mid-term, causing service-based revenues to grow at an annualized rate of over 8%
- In the long-term, the projected opportunity is anticipated to be well distributed across various packaging formats, scales of operation and sizes of contract service providers
- Eminent representatives from prominent ophthalmic drug contract manufacturing companies confirm the importance of outsourcing, highlighting prevalent and anticipated trends within this domain
For more information, please visit https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html
Table of Contents
- PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
EXECUTIVE SUMMARY
- INTRODUCTION
3.1. Context and Background
3.2. Introduction to Ophthalmology
3.2.1. Chronic Eye Conditions and Associated Economic Burden
3.3. Common Ophthalmic Drug Dosage Forms
3.3.1. Types of Oral Drug Formulations
3.3.1.1. Tablets
3.3.1.2. Capsules
3.3.1.3. Eye Supplements
3.3.2. Types of Semi-solid Formulations
3.3.2.1. Ointments
3.5.2.2. Gels
3.5.2.3. Emulsions
3.3.3. Types of Liquid Drug Formulations
3.3.3.1. Solutions
3.3.3.2. Suspensions
3.5.3.1. Sterile Injectables
3.3.4. Intraocular Inserts
3.4. Common Primary Packaging Formats for Ophthalmic Drugs
3.5. Overview of Contract Manufacturing
3.6. Outsourcing in the Ophthalmology Industry
3.6.1. Need for Outsourcing
3.6.2. Commonly Outsourced Operations
3.6.3. Guidelines for Selecting a Contract Manufacturing Organization (CMO) Partner
3.6.4. Advantages of Outsourcing Manufacturing Operations
3.6.5. Challenges Associated with Ophthalmic Drugs Contract Manufacturing
3.6.6. Growth Drivers and Roadblocks to Ophthalmic Drugs Contract Manufacturing
3.6.7. Recent Developments and Upcoming Trends
- CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Ophthalmic Drug Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Geographical Location
4.2.5. Analysis by Location of Manufacturing Facilities
4.2.6. Analysis by Type of Product
4.2.7. Analysis by Type of FDF Manufactured
4.2.8. Analysis by Type of Primary Packaging
4.2.9. Analysis by Type of Service(s) Offered
4.2.10. Analysis by Regulatory Accreditations / Certifications
- COMPANY COMPETITVENESS ANALYSIS
5.1. Chapter Overview
5.2. Key Assumptions and Methodology
5.3. Competitiveness Analysis: Ophthalmic API Contract Manufacturers
5.3.1. Ophthalmic API Contract Manufacturers in North America
5.3.2. Ophthalmic API Contract Manufacturers in Europe
5.3.3. Ophthalmic API Contract Manufacturers in Asia-Pacific
5.4. Competitiveness Analysis: Ophthalmic Drug FDF Contract Manufacturers
5.4.1. Ophthalmic Drug FDF Contract Manufacturers in North America
5.4.2. Ophthalmic Drug FDF Contract Manufacturers in Europe
5.4.3. Ophthalmic Drug FDF Contract Manufacturers in Asia-Pacific
- OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. Akorn
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Service Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. Catalent
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Service Portfolio
6.2.4. Recent Developments and Future Outlook
6.4. Cayman Chemical
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Pillar5 Pharma
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Sterling Pharmaceutical Services
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Recent Developments and Future Outlook
- OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN EUROPE: COMPANY PROFILES
7.1. Chapter Overview
7.2. FARMIGEA
7.2.1. Company Overview
7.2.2. Service Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. Lomapharm
7.3.1. Company Overview
7.3.2. Service Portfolio
7.3.3 Recent Developments and Future Outlook
7.4. Medichem
7.4.1. Company Overview
7.4.2. Service Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Recipharm
7.5.1. Company Overview
7.5.2. Financial Information
7.5.3. Service Portfolio
7.5.4. Recent Developments and Future Outlook
7.6. Salvat
7.6.1. Company Overview
7.6.2 Service Portfolio
7.6.3. Recent Developments and Future Outlook
- OPHTHALMIC DRUGS CONTERACT MANUFACTURING IN ASIA-PACIFIC: COMPANY PROFILES
8.1. Chapter Overview
8.2. Akums
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. Bal Pharma
8.3.1. Company Overview
8.3.2. Financial Information
8.3.3. Service Portfolio
8.2.4. Recent Developments and Future Outlook
8.4. Entod Pharmaceuticals
8.4.1. Company Overview
8.4.2. Service Portfolio
8.4.3. Recent Developments and Future Outlook
8.5. Glenmark Pharmaceuticals
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Recent Developments and Future Outlook
8.6. Indiana Ophthalmics
8.6.1. Company Overview
8.6.2. Service Portfolio
8.6.3. Recent Developments and Future Outlook
8.7. Sunways India
8.7.1. Company Overview
8.7.2. Service Portfolio
8.7.3. Recent Developments and Future Outlook
- CLINICAL TRIAL ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Ophthalmic Drug Trial Analysis
9.3.1. Analysis by Trial Registration Year
9.3.2. Geographical Analysis by Number of Clinical Trials
9.3.3. Geographical Analysis by Enrolled Patient Population
9.3.4. Analysis by Phase of Development
9.3.5. Analysis by Trial Recruitment Status
9.3.6. Analysis by Type of Sponsor / Collaborator
9.3.7. Most Active Players in Terms of Number of Registered Trials
9.3.8. Analysis by Type of Intervention
9.3.9. Analysis by Trial Focus
9.3.10. Analysis by Target Indication
9.3.11. Benchmark Analysis of Active Industry Players
- CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Ophthalmic API Contract Manufacturers: Global Production Capacity
10.3.1. Analysis by Geography
10.3.1.1. Overall Production Capacity in North America
10.3.1.2. Overall Production Capacity in Europe
10.3.1.3. Overall Production Capacity in Asia-Pacific
10.3.1.4. Overall Production Capacity in Rest of the World
10.3.2. Analysis by Scale of Operation
10.3.2.1. Overall Clinical Scale Production Capacity
10.3.2.2. Overall Commercial Scale Production Capacity
10.3.2.3. Both Clinical and Commercial Scale Production Capacity
Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.” The report features an extensive study on the contract service providers within the biopharmaceutical industry.
The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs.
Amongst other elements, the report includes:A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Commonly Outsourced Business OperationsActive Pharmaceutical Ingredients (API)Finished Dosage Formulations (FDF)Types of Expression SystemMammalianMicrobialOthersCompany SizeSmallMid-SizedLarge and Very LargeScale of OperationPreclinicalClinicalCommercialKey Geographical Region North AmericaEuropeAsia-PacificRest of the World The report also features detailed transcripts of discussions held with the following experts:Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)Birgit Schwab, Senior Manager Strategic Marketing, Rentschler BiotechnologieChristian Bailly, Director of CDMO, Pierre FabreClaire Otjes, Assistant Marketing Manager, Batavia BiosciencesDavid C Cunningham, Director Corporate Development, Goodwin BiotechnologyDietmar Katinger, Chief Executive Officer, Polymun ScientificDenis Angioletti, Chief Commercial Officer, Cerbios-PharmaJeffrey Hung, Chief Commercial Officer, Vigene BiosciencesKevin Daley, Director Pharmaceuticals, NovasepMark Wright, Site Head, Grangemouth, Piramal HealthcareNicolas Grandchamp, R Leader, GEG TechRaquel Fortunato, Chief Executive Officer, GenIbet BiopharmaceuticalsSebastian Schuck, Head of Business Development, Wacker BiotechStephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth BiotechnologiesTatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactoryTim Oldham, Chief Executive Officer, Cell Therapies To request for sample report - https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html Key companies covered in the report3P BiopharmaceuticalsAbzenaAlbany Molecular ResearchBioVectraBioXcellence (Boehringer Ingelheim)CelonicCharles River LaboratoriesChemPartnerCobra BiologicsCordenPharmaCytovance BiologicsGE HealthcareGoodwin BiotechnologyGrand River Aseptic ManufacturingIDT BiologikaKBI BioPharmaKemwell BiopharmaLFB BiomanufacturingMeridian Life SciencePatheonPfizer CentreOnePX'TherapeuticsSamsung BioLogicsSanofi, CEPiAThermo Fisher ScientificVetter Pharma International For more information please click on the following link:Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030 Other Recent OfferingsCell Therapy Manufacturing Market (3rd Edition), 2019-2030Antibody Contract Manufacturing Market, 2020-2030China Biopharmaceutical Contract Manufacturing Market, 2020-2030Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.
The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.
If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected] - https://www.facebook.com/RootsAnalysis
Therefore, the use of technology can save time and money, while providing a far better understanding of the relationships between different formulations and processes parameters.Key Drivers, Restraints, and Opportunities of AI in Pharma and Biotech MarketAdoption of artificial intelligence (AI) in the drug discovery market in developing regions such as APAC is increasing, thanks to the expansion of pharmaceutical industries by collaborating with other industries and rise in demand to reduce drug discovery time.
Furthermore, the expansion of biotechnology industries is estimated to offer significant opportunities for the market.An estimated 50% of U.S. citizens are affected by at least one chronic condition; consequently, the pharmaceutical segment of the healthcare industry is projected to be positively impacted by the expected trend of AI adoption.All top 10 so-called giant pharma companies (namely Novartis, Roche, Pfizer, Merck, AstraZeneca, GlaxoSmithKline, Sanofi, Abbvie, Bristol-Myers Squibb, and Johnson & Johnson) have either expressly collaborated with or acquired AI technologies to take advantage of the opportunities AI brings to the table.
Industry leaders are presently focused on the development of more efficient methods, and machine learning is emerging as a possible solution.The current machine learning initiatives of the top five pharmaceutical and biotechnology companies reveal trends within the following areas:Digital coaching solutions – Utilization of web-based technologies to simulate one-on-one coaching sessions so that all patients can have the benefit of a uniquely devised medication program.For instance: Johnson & Johnson’s Patient Athlete programPersonalized medicine – Personalized medicine, also called precision medicine, maybe a medical model that separates people into different groups—with medical decisions, practices, interventions, and/or products being tailored to the individual patient supported their predicted response or risk of disease.For instance.
Unlike other applications within healthcare facilities, drug discovery seems to own a clearer path to adoption.Recently, robots became more collaborative with humans and are more easily trained by moving them through the desired task.
Over time, it seems likely that an equivalent improvement in intelligence that we have seen in other areas of AI would be incorporated into physical robots.Surgical robots initially approved in the U.S. in 2000, provided ‘superpowers’ to surgeons, improving their ability to examine, create precise and minimally invasive incisions, and stitch wounds.
Common surgical procedures using robotic surgery include gynecologic surgery, prostate surgery, and head and neck surgery.Pre Book Ai In Pharma And Biotech Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=79399=S North America to Capture Major Share of Global Market of AI in Pharma & BiotechNorth America is expected to account for a major share of the global market of AI in Pharma and Biotech due to the high prevalence of chronic diseases among the population.
Softcon Systems brings you automation solutions specific to the pharmaceutical industry – we will work with you to develop and implement ideal solutions specific to your requirements.
Automation at every point of the value chain will enable the pharma companies to get pharmaceuticals from the lab to the patient more quickly.We design systems that help pharmaceutical and biotech companies to achieve operational excellence, reduce time to market and meet all industry standards and regulations.
“Global Streetcar Market 2024” Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2024 is Provided to Determine the Market Potential.
In this report, our team research the global Streetcar market by type, application,
Request a sample of Streetcar Market report @ http://www.arcognizance.com/enquiry-sample/445675
Geographically, global Streetcar market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
